The National Institute for Health and Care Excellence

Routine NHS access to spinal muscular atrophy treatments offers new hope for patients and families

SMA is a rare, inherited condition that causes progressive muscle weakness, affecting movement, breathing and swallowing. Without treatment, the condition can lead to severe disability and, in its ...
The National Institute for Health and Care Excellence

Neonatal infection guidance updated to allow home antibiotic treatment for some babies

Some of these babies will need to stay in hospital. But our new guidance says babies born after 35 weeks who are on intravenous antibiotics can be switched to a simple liquid oral antibiotic and taken ...
The National Institute for Health and Care Excellence

'I no longer feel asthmatic': more than a million people now using new style inhalers

For decades, the little blue inhaler was a lifeline for millions of people with asthma. But doctors now know it can make the condition worse - and a quiet revolution in treatment is already ...
National Institute for Health and Care Excellence

Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity

There is a commercial access agreement for semaglutide. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

NICE approves Duchenne muscular dystrophy treatment givinostat after commercial deal sealed

Today’s final draft guidance says givinostat (also called Duvyzat and made by ITF Pharma) can be used to treat Duchenne muscular dystrophy (DMD) in people aged 6 and over who are able to walk or stand ...
National Institute for Health and Care Excellence

Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment

There is a simple discount patient access scheme for zanidatamab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
The National Institute for Health and Care Excellence

NICE announces the appointment of Dr Adrian Hayter as its new chief medical office

NICE today announced the appointment of Dr Adrian Hayter as its new chief medical officer, bolstering the institute’s clinical leadership, following the appointment of CEO Professor Jonathan Benger ...
National Institute for Health and Care Excellence

Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida (terminated appraisal)

NICE is unable to make a recommendation on oxybutynin hydrochloride (Vesoxx) for managing neurogenic detrusor overactivity. This is because the company did not provide an evidence submission.
National Institute for Health and Care Excellence

Published: Guidance, quality standards and advice

Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards ...
National Institute for Health and Care Excellence

Older people

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.
National Institute for Health and Care Excellence

Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease [ID4043]

Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease [ID4043] ...
National Institute for Health and Care Excellence

Pembrolizumab for neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma

There is a commercial access agreement for pembrolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact keiron.hughes@msd.com ...